# Elevating Circulating L‐Kynurenine Promotes Frailty in Aging Mice

**Authors:** Mia Y. Kawaida, Abigail L. Tice, Samuel Alvarez, Jacob A. Lackey, Benjamin Izaguirre, Qingping Yang, Lan Wei‐LaPierre, Russell T. Hepple, Terence E. Ryan

PMC · DOI: 10.1002/jcsm.70214 · Journal of Cachexia, Sarcopenia and Muscle · 2026-02-02

## TL;DR

Elevated L-Kynurenine worsens age-related frailty in mice, but increased PGC1α in muscles helps protect against this decline.

## Contribution

This study shows that PGC1α overexpression in skeletal muscle mitigates L-Kyn-induced frailty in aging mice.

## Key findings

- MCK-PGC1α transgenic mice showed significantly higher KAT expression compared to wildtype mice.
- L-Kyn diet increased frailty in wildtype mice, but this was mitigated by MCK-PGC1α overexpression.
- MCK-PGC1α mice had improved mitochondrial function regardless of L-Kyn diet.

## Abstract

L‐Kynurenine (L‐Kyn), a product of tryptophan catabolism, increases with age and has been associated with reduced physical function and increased frailty in humans. Robustly expressed in skeletal muscle, kynurenine aminotransferases (KATs) degrade L‐Kyn into kynurenic acid and are regulated by the transcriptional co‐regulator peroxisome proliferator–activated receptor gamma coactivator 1‐alpha (PGC1α).

The study investigated (1) if elevating L‐Kyn levels via a diet intervention exacerbates an age‐related decline in physical, muscle and mitochondrial functions and (2) if transgenic expression of PGC1α in skeletal muscle (MCK‐PGC1α) protects against age‐dependent L‐Kyn associated pathology in a cohort of aging MCK‐PGC1α transgenic mice and their wildtype littermates of both sexes (n = 262). Physical function was assessed longitudinally from 16 to 24 months of age using treadmill endurance capacity, grip strength, walking speed and daily physical activity. Muscle function was assessed in situ using nerve‐mediated contraction of the soleus muscle. Mitochondrial energetics were assessed using high resolution respirometry and fluorescence spectroscopy.

MCK‐PGC1α transgenic mice had significantly higher KAT expression ~2–5‐fold compared with wildtype littermates (p < 0.0001 for all isoforms). A main effect of L‐Kyn diet was observed for decreasing treadmill endurance capacity and daily physical activity in male mice (p ≦ 0.002). A main effect of L‐Kyn diet for decreasing maximal walking speed only was found in female mice (p = 0.037). Correspondingly, L‐Kyn increased frailty prevalence in male (+17%) and female (+26%) wildtype mice (p = 0.025 and 0.0001 respectively), which was mitigated by MCK‐PGC1α in both sexes. Soleus muscle strength and power were not impacted by diet or genotype in either sex (p > 0.5). Mitochondrial oxidative phosphorylation function in male and female MCK‐PGC1α mice was greater than wild type mice regardless of diet (p < 0.04), which is likely driven by upregulated expression of mitochondrial biogenesis related genes.

We conclude that PGC1α overexpression in skeletal muscle mitigates the exacerbation of physical frailty induced by elevated circulating L‐Kyn in aging mice, in part through increased skeletal muscle capacity for L‐Kyn metabolism due to PGC1α‐induced increase in muscle KAT expression.

## Linked entities

- **Genes:** PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891]
- **Chemicals:** L-Kynurenine (PubChem CID 161166), kynurenic acid (PubChem CID 3845)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Il15 (interleukin 15) [NCBI Gene 16168] {aka IL-15}, Tstd1 (thiosulfate sulfurtransferase (rhodanese)-like domain containing 1) [NCBI Gene 226654] {aka EG226654, Gm4848, KAT}, GOT2 (glutamic-oxaloacetic transaminase 2) [NCBI Gene 2806] {aka DEE82, KAT4, KATIV, KYAT4, mitAAT}, Got2 (glutamatic-oxaloacetic transaminase 2, mitochondrial) [NCBI Gene 14719] {aka FABP-pm, Got-2, Kyat4, mAspAT}, IDO1 (indoleamine 2,3-dioxygenase 1) [NCBI Gene 3620] {aka IDO, IDO-1, INDO}, KYAT3 (kynurenine aminotransferase 3) [NCBI Gene 56267] {aka CCBL2, KAT3, KATIII}, Tdo2 (tryptophan 2,3-dioxygenase) [NCBI Gene 56720] {aka TDO, TO, chky}, TDO2 (tryptophan 2,3-dioxygenase) [NCBI Gene 6999] {aka HYPTRP, TDO, TO, TPH2, TRPO}, Nek1 (NIMA (never in mitosis gene a)-related expressed kinase 1) [NCBI Gene 18004] {aka D8Ertd790e, kat}, KYAT1 (kynurenine aminotransferase 1) [NCBI Gene 883] {aka CCBL1, GTK, KAT1, KATI}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, Il7 (interleukin 7) [NCBI Gene 16196] {aka A630026I06Rik, Il-7, hlb368}, Ido1 (indoleamine 2,3-dioxygenase 1) [NCBI Gene 15930] {aka Ido, Indo}, Aadat (aminoadipate aminotransferase) [NCBI Gene 23923] {aka Aadt, KATII, Kat2, Kyat2, mKat-2}, Kmo (kynurenine 3-monooxygenase) [NCBI Gene 98256], Taf1 (TATA-box binding protein associated factor 1) [NCBI Gene 270627] {aka B430306D02Rik, Ccg-1, Ccg1, KAT4, N-TAF1, TAFII250}, Kyat3 (kynurenine aminotransferase 3) [NCBI Gene 229905] {aka Ccbl2, KATIII, Kat3}, PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, Ckm (creatine kinase, muscle) [NCBI Gene 12715] {aka CPK-M, Ckmm, M-CK, MCK}, Kynu (kynureninase) [NCBI Gene 70789] {aka 4432411A05Rik}, Ppargc1a (peroxisome proliferative activated receptor, gamma, coactivator 1 alpha) [NCBI Gene 19017] {aka A830037N07Rik, Gm11133, PGC-1, PPARGC-1-alpha, Pgc-1alpha, Pgc1}, Kyat1 (kynurenine aminotransferase 1) [NCBI Gene 70266] {aka 2010009K05Rik, Ccbl1, Gtk, Kat1, KatI}
- **Diseases:** decline in physical (MESH:D059445), muscle (MESH:D019042), impaired adaptive immunity (MESH:D018489), decline in physical function (MESH:D060825), weight gain (MESH:D015430), Chronic inflammation (MESH:D007249), Sarcopenic Status (MESH:D013226), Sarcopenia (MESH:D055948), reduced physical function (MESH:D001523), loss of muscle mass (MESH:C536030), Frailty (MESH:D000073496), mitochondrial dysfunction (MESH:D028361), age (MESH:D019588), muscle atrophy (MESH:D009133), muscle fatigue (MESH:D005221), neurotoxic (MESH:D020258)
- **Chemicals:** aspartate (MESH:D001224), oxygen (MESH:D010100), phosphocreatine (MESH:D010725), acid (MESH:D000143), quinolinic acid (MESH:D017378), malate (MESH:C030298), creatine (MESH:D003401), H2O2 (MESH:D006861), NAD+ (MESH:D009243), palmitoylcarnitine (MESH:D010172), KYN (MESH:D007737), L (MESH:D007930), pyruvate (MESH:D019289), Trp (MESH:D014364), tetramethylrhodamine methyl ester (MESH:C401833), anthranilic acid (MESH:C031385), Cr (MESH:D002857), kynurenic acid (MESH:D007736), 3-hydroxykynurenine (MESH:C005045), CSA (-)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Drosophila melanogaster (fruit fly, species) [taxon 7227], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** C57BL/6J — Mus musculus (Mouse), Transformed cell line (CVCL_C0MW)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12862278/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12862278/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC12862278/full.md

---
Source: https://tomesphere.com/paper/PMC12862278